{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:29:59Z","timestamp":1788294599246,"version":"build-2803163510"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100010803","name":"Department of Biotechnology, Government of West Bengal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cytometry Part B Clinical"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Immunophenotypic profile and post\u2010therapy alteration in antigenic expression were evaluated in normal, reactive, and aberrant plasma cells (NPC, RPC, and APC) for impact on measurable residual disease (MRD) assessment in multiple myeloma (MM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Samples from non\u2010MM staging marrow (<jats:italic>n\u2009=<\/jats:italic>\u00a030), Hodgkin's lymphoma (<jats:italic>n\u2009=<\/jats:italic>\u00a030) and MM (<jats:italic>n\u2009=<\/jats:italic>\u00a0724) were prospectively evaluated for expression profiles of NPC, RPC, and APC using antigens recommended in consensus guidelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Polyclonal NPC\u2010RPC demonstrated aberrations for all antigens evaluated with a higher frequency of aberrancies in post\u2010therapy samples compared to treatment na\u00efve samples (<jats:italic>p\u2009&lt;<\/jats:italic>\u00a00.001%). Immunomodulation in APC was observed in 79% of post\u2010therapy samples with a change in expression of 1, 2, and \u22653 antigens in 19.9%, 15.6%, and 43.5% samples, respectively. In 13.4% of samples, APC showed no aberrancy and aberrant status was assigned based on cytoplasmic light chain restriction (cyLCR) alone. 9% samples with an admixture of NPC and APC displayed normal cytoplasmic kappa to lambda ratio (cyKLR) when the percentage of APC of total PC (neoplastic plasma cell index, NPCI), was below 25% and 50% for kappa and lambda restricted cases, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The panorama and high frequency of antigenic aberrations on polyclonal PC signify the importance of MRD assay validation on a large cohort under normal and reactive conditions. Frequent Immunophenotypic shifts in APC re\u2010confirm the redundancy of baseline immunophenotype for MRD evaluation. Small clones of APC may be missed by assessment of cyKLR alone and therefore, surface marker aberrancy supported by cyLCR is required for definitive assignment of residual APC.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cyto.b.22068","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T14:49:28Z","timestamp":1649342968000},"page":"209-219","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Relevance of polyclonal plasma cells and post\u2010therapy immunomodulation in measurable residual disease assessment in multiple myeloma"],"prefix":"10.1002","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-6210","authenticated-orcid":false,"given":"Nupur","family":"Das","sequence":"first","affiliation":[{"name":"Laboratory Oncology Unit Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meetu","family":"Dahiya","sequence":"additional","affiliation":[{"name":"Laboratory Oncology Unit Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5364-4086","authenticated-orcid":false,"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[{"name":"Laboratory Oncology Unit Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Rai","sequence":"additional","affiliation":[{"name":"Laboratory Oncology Unit Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj","family":"Singh","sequence":"additional","affiliation":[{"name":"Laboratory Oncology Unit Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Laboratory Oncology Unit Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit K.","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Gogia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dr. B.R. Ambedkar IRCH, All India Institute of Medical Sciences  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21228"},{"key":"e_1_2_6_3_1","first-page":"49","article-title":"Analysis of bone marrow plasma cells in patients with solitary bone plasmacytoma","volume":"7","author":"Bhaskar A.","year":"2009","journal-title":"Cancer Therapy"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1309\/8UVF7YQ1D4D4ETQV"},{"key":"e_1_2_6_5_1","first-page":"1","article-title":"Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with pattern\u2010based recognition","author":"Das N.","year":"2022","journal-title":"Cytometry Part B: Clinical Cytometry"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20408"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403559"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP1GYI7EHQYUYK"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.122"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2010.09.002"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2012-200881"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20601"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11080"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21789"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21754"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2011.01317.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21249"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21106"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.12.007"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-018-0330-6"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9122666"}],"container-title":["Cytometry Part B: Clinical Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.22068","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cyto.b.22068","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.22068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T14:51:35Z","timestamp":1692975095000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.b.22068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1002\/cyto.b.22068"],"URL":"https:\/\/doi.org\/10.1002\/cyto.b.22068","archive":["Portico"],"relation":{},"ISSN":["1552-4949","1552-4957"],"issn-type":[{"value":"1552-4949","type":"print"},{"value":"1552-4957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"assertion":[{"value":"2021-07-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}